Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Teaching Rounds | 12 | 2023 | 253 | 4.560 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2018 | 503 | 1.160 |
Why?
|
| Primary Prevention | 4 | 2022 | 1167 | 1.040 |
Why?
|
| Diverticulitis | 1 | 2023 | 171 | 0.760 |
Why?
|
| Practice Guidelines as Topic | 11 | 2023 | 7282 | 0.660 |
Why?
|
| Cannabinoids | 1 | 2021 | 166 | 0.640 |
Why?
|
| Dementia | 2 | 2023 | 2518 | 0.620 |
Why?
|
| Aspirin | 2 | 2021 | 3283 | 0.610 |
Why?
|
| Patient Selection | 2 | 2020 | 4216 | 0.610 |
Why?
|
| Diabetic Neuropathies | 1 | 2021 | 400 | 0.590 |
Why?
|
| Gout Suppressants | 1 | 2018 | 166 | 0.590 |
Why?
|
| Early Detection of Cancer | 3 | 2022 | 3086 | 0.580 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2021 | 3070 | 0.580 |
Why?
|
| Clostridium Infections | 1 | 2023 | 548 | 0.560 |
Why?
|
| Gynecological Examination | 1 | 2015 | 33 | 0.530 |
Why?
|
| Hot Flashes | 1 | 2018 | 316 | 0.510 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2018 | 386 | 0.510 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2018 | 1203 | 0.490 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3255 | 0.480 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2020 | 1856 | 0.480 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 1020 | 0.470 |
Why?
|
| Menopause | 2 | 2018 | 1626 | 0.450 |
Why?
|
| Atherosclerosis | 2 | 2021 | 3444 | 0.430 |
Why?
|
| Thyroxine | 1 | 2016 | 667 | 0.430 |
Why?
|
| Hypercholesterolemia | 2 | 2017 | 1151 | 0.420 |
Why?
|
| Gout | 1 | 2018 | 573 | 0.410 |
Why?
|
| Cardiovascular Diseases | 4 | 2022 | 15160 | 0.400 |
Why?
|
| Mass Screening | 6 | 2023 | 5253 | 0.390 |
Why?
|
| Hypothyroidism | 1 | 2016 | 658 | 0.390 |
Why?
|
| Risk Assessment | 11 | 2022 | 23336 | 0.390 |
Why?
|
| Bone Density Conservation Agents | 1 | 2018 | 772 | 0.380 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 745 | 0.370 |
Why?
|
| Prostate-Specific Antigen | 1 | 2019 | 2494 | 0.340 |
Why?
|
| Depressive Disorder | 2 | 2017 | 3747 | 0.340 |
Why?
|
| Guideline Adherence | 2 | 2019 | 2265 | 0.340 |
Why?
|
| Inpatients | 1 | 2020 | 2518 | 0.320 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 1671 | 0.300 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 2873 | 0.290 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 2200 | 0.280 |
Why?
|
| Breast Neoplasms | 8 | 2018 | 20824 | 0.270 |
Why?
|
| Israel | 2 | 2018 | 796 | 0.270 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3047 | 0.260 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2009 | 360 | 0.260 |
Why?
|
| Analgesics | 2 | 2021 | 1040 | 0.250 |
Why?
|
| Colorectal Neoplasms | 3 | 2022 | 6773 | 0.240 |
Why?
|
| Humans | 46 | 2023 | 744366 | 0.240 |
Why?
|
| Cyclohexanols | 1 | 2004 | 127 | 0.230 |
Why?
|
| Serotonin Agents | 1 | 2002 | 29 | 0.220 |
Why?
|
| Barrett Esophagus | 1 | 2006 | 494 | 0.210 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2011 | 1186 | 0.200 |
Why?
|
| Female | 28 | 2023 | 380193 | 0.200 |
Why?
|
| Tension-Type Headache | 1 | 2002 | 77 | 0.190 |
Why?
|
| Androstadienes | 2 | 2016 | 345 | 0.190 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 5035 | 0.190 |
Why?
|
| Primary Health Care | 3 | 2016 | 4557 | 0.180 |
Why?
|
| Middle Aged | 18 | 2023 | 213390 | 0.180 |
Why?
|
| Postmenopause | 1 | 2009 | 2460 | 0.180 |
Why?
|
| Gastroesophageal Reflux | 1 | 2006 | 782 | 0.170 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2004 | 546 | 0.170 |
Why?
|
| Mammography | 5 | 2018 | 2475 | 0.170 |
Why?
|
| Risk Reduction Behavior | 2 | 2016 | 1125 | 0.170 |
Why?
|
| Aromatase Inhibitors | 2 | 2016 | 490 | 0.170 |
Why?
|
| Panic Disorder | 1 | 2002 | 616 | 0.160 |
Why?
|
| Aged | 17 | 2023 | 163288 | 0.160 |
Why?
|
| Tamoxifen | 2 | 2016 | 981 | 0.160 |
Why?
|
| Lyme Disease | 1 | 2003 | 621 | 0.150 |
Why?
|
| Colchicine | 1 | 2018 | 244 | 0.150 |
Why?
|
| Preventive Health Services | 1 | 2022 | 575 | 0.150 |
Why?
|
| Administration, Inhalation | 1 | 2020 | 1105 | 0.150 |
Why?
|
| Alendronate | 1 | 2018 | 171 | 0.150 |
Why?
|
| Feces | 1 | 2022 | 1401 | 0.140 |
Why?
|
| Risk Factors | 7 | 2022 | 72296 | 0.140 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 11126 | 0.140 |
Why?
|
| Patient Satisfaction | 2 | 2008 | 3395 | 0.130 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2016 | 129 | 0.130 |
Why?
|
| Neuroprotective Agents | 1 | 2002 | 941 | 0.130 |
Why?
|
| Borderline Personality Disorder | 1 | 2003 | 736 | 0.130 |
Why?
|
| Pravastatin | 1 | 2017 | 395 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 11726 | 0.130 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2018 | 366 | 0.130 |
Why?
|
| Colonoscopy | 1 | 2023 | 1367 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 7182 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 13693 | 0.130 |
Why?
|
| Acetaminophen | 1 | 2018 | 545 | 0.120 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 3611 | 0.120 |
Why?
|
| Hypnotics and Sedatives | 1 | 2002 | 1162 | 0.120 |
Why?
|
| Urology | 1 | 2019 | 399 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2023 | 9145 | 0.120 |
Why?
|
| Prednisone | 1 | 2018 | 1574 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 1 | 2002 | 1148 | 0.120 |
Why?
|
| Diphosphonates | 1 | 2018 | 623 | 0.110 |
Why?
|
| Osteoporotic Fractures | 1 | 2018 | 401 | 0.110 |
Why?
|
| Complementary Therapies | 1 | 2017 | 486 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 3922 | 0.110 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 2355 | 0.110 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 551 | 0.110 |
Why?
|
| Psychotherapy | 2 | 2017 | 1642 | 0.110 |
Why?
|
| Hypoglycemia | 1 | 2019 | 861 | 0.100 |
Why?
|
| Comparative Effectiveness Research | 1 | 2017 | 680 | 0.100 |
Why?
|
| Absorptiometry, Photon | 1 | 2018 | 1725 | 0.100 |
Why?
|
| United States | 9 | 2022 | 69872 | 0.100 |
Why?
|
| Internal Medicine | 1 | 2019 | 1009 | 0.100 |
Why?
|
| Hospice Care | 3 | 2003 | 672 | 0.100 |
Why?
|
| Male | 13 | 2022 | 350115 | 0.100 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2004 | 1813 | 0.100 |
Why?
|
| Antazoline | 1 | 1990 | 6 | 0.090 |
Why?
|
| Naphazoline | 1 | 1990 | 7 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 979 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 1131 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 4933 | 0.090 |
Why?
|
| Quality of Life | 2 | 2018 | 12802 | 0.090 |
Why?
|
| Breast | 1 | 2018 | 1970 | 0.090 |
Why?
|
| Acute Disease | 1 | 2020 | 7147 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 950 | 0.090 |
Why?
|
| Renal Artery | 1 | 2011 | 399 | 0.080 |
Why?
|
| Conjunctivitis, Allergic | 1 | 1990 | 130 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2282 | 0.080 |
Why?
|
| Physician's Role | 1 | 2015 | 943 | 0.080 |
Why?
|
| Recurrence | 1 | 2018 | 8340 | 0.070 |
Why?
|
| Watchful Waiting | 1 | 2011 | 492 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3531 | 0.070 |
Why?
|
| Omeprazole | 1 | 2006 | 112 | 0.070 |
Why?
|
| Cognition | 1 | 2023 | 6770 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2021 | 63107 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 3677 | 0.070 |
Why?
|
| Palliative Care | 1 | 2020 | 3493 | 0.060 |
Why?
|
| Bone Density | 1 | 2018 | 3468 | 0.060 |
Why?
|
| Esophagoscopy | 1 | 2006 | 390 | 0.060 |
Why?
|
| Parapsoriasis | 1 | 2003 | 2 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 12961 | 0.060 |
Why?
|
| Cardiology | 1 | 2015 | 1668 | 0.060 |
Why?
|
| Imidazoles | 1 | 1990 | 1206 | 0.060 |
Why?
|
| Carcinoma, Lobular | 1 | 2008 | 484 | 0.060 |
Why?
|
| Smoking | 1 | 2020 | 8987 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 2020 | 0.060 |
Why?
|
| Clonazepam | 1 | 2002 | 136 | 0.050 |
Why?
|
| Proton Pump Inhibitors | 1 | 2006 | 526 | 0.050 |
Why?
|
| Decision Making | 1 | 2015 | 3888 | 0.050 |
Why?
|
| SEER Program | 5 | 2005 | 1507 | 0.050 |
Why?
|
| Relaxation Therapy | 1 | 2002 | 178 | 0.050 |
Why?
|
| Advance Care Planning | 1 | 2008 | 662 | 0.050 |
Why?
|
| Terminally Ill | 1 | 2003 | 238 | 0.050 |
Why?
|
| Hospices | 1 | 2003 | 265 | 0.050 |
Why?
|
| Attitude to Death | 1 | 2003 | 382 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 20130 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2005 | 956 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 2002 | 390 | 0.040 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 57776 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2002 | 421 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 4839 | 0.040 |
Why?
|
| Adult | 7 | 2016 | 214052 | 0.040 |
Why?
|
| Risk | 2 | 2007 | 9688 | 0.040 |
Why?
|
| Physical Examination | 1 | 2004 | 1237 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2003 | 694 | 0.040 |
Why?
|
| Managed Care Programs | 1 | 2003 | 950 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2002 | 6489 | 0.040 |
Why?
|
| Obesity | 1 | 2019 | 12746 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2003 | 865 | 0.040 |
Why?
|
| Psychotropic Drugs | 1 | 2003 | 894 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 3799 | 0.030 |
Why?
|
| Health Surveys | 1 | 2004 | 4036 | 0.030 |
Why?
|
| Depression | 2 | 2003 | 7759 | 0.030 |
Why?
|
| Medicare | 3 | 2003 | 6566 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2005 | 11031 | 0.020 |
Why?
|
| Hyperemia | 1 | 1990 | 225 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2003 | 13104 | 0.020 |
Why?
|
| Advance Directives | 1 | 2008 | 246 | 0.020 |
Why?
|
| Conjunctiva | 1 | 1990 | 494 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2006 | 6459 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1990 | 1958 | 0.020 |
Why?
|
| Neoplasms | 2 | 2003 | 21696 | 0.010 |
Why?
|
| Hospitalization | 1 | 2003 | 10259 | 0.010 |
Why?
|
| Pacific Islands | 1 | 2003 | 50 | 0.010 |
Why?
|
| Asia | 1 | 2005 | 609 | 0.010 |
Why?
|
| Allergens | 1 | 1990 | 1320 | 0.010 |
Why?
|
| Georgia | 1 | 2000 | 186 | 0.010 |
Why?
|
| Connecticut | 1 | 2000 | 366 | 0.010 |
Why?
|
| Insurance Claim Reporting | 1 | 2000 | 163 | 0.010 |
Why?
|
| Washington | 1 | 2000 | 313 | 0.010 |
Why?
|
| Length of Stay | 2 | 2003 | 6311 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 3480 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 2902 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 2419 | 0.010 |
Why?
|
| Medical Record Linkage | 1 | 2000 | 284 | 0.010 |
Why?
|
| Proportional Hazards Models | 2 | 2003 | 12356 | 0.010 |
Why?
|
| Retrospective Studies | 5 | 2003 | 77460 | 0.010 |
Why?
|
| Terminal Care | 1 | 2008 | 1694 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 8642 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 12244 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2003 | 2494 | 0.010 |
Why?
|
| Cause of Death | 1 | 2000 | 3582 | 0.010 |
Why?
|
| Logistic Models | 1 | 2003 | 13409 | 0.000 |
Why?
|
| Survival Analysis | 1 | 2000 | 10252 | 0.000 |
Why?
|
| Registries | 1 | 2003 | 8091 | 0.000 |
Why?
|
| Age Factors | 1 | 2003 | 18373 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 25039 | 0.000 |
Why?
|
| Time Factors | 1 | 2003 | 40075 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2000 | 40559 | 0.000 |
Why?
|
Concepts
(198)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(43)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_